Insider · CIK 0001569769
Manmeet Singh Soni
Files at RETA (REATA PHARMACEUTICALS INC), SMMT (Summit Therapeutics Inc.), PLSE (Pulse Biosciences, Inc.). First filing Mar 6, 2023, latest Jun 4, 2026.
In brief
Manmeet Singh Soni files SEC Form 4 as CFO, COO, director and president at RETA (REATA PHARMACEUTICALS INC), and also at SMMT (Summit Therapeutics Inc.), PLSE (Pulse Biosciences, Inc.). Since Mar 6, 2023, Manmeet Singh Soni has reported 2 open-market buys worth $5.7M and 2 open-market sells worth $368k, the latest filed on Jun 4, 2026.
A track record needs three past buys with six months of prices behind them; Manmeet Singh Soni has 1, so none is measured yet.
The newest scored trade: bought $722k of SMMT on Jun 4, 2026, filed Jun 4, 2026, scored 76 (notable). In the last 12 months: 1 buy worth $722k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SMMT: Summit Therapeutics Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 76Notable | Summit Therapeutics Inc. | $722k 50,000 shares | +2% | +7% from low-49% from high | |
| 61Notable | SMMTbuy Summit Therapeutics Inc. | $5.0M 2,976,190 shares | - | +147% from low-69% from high | |
| 44Moderate | REATA PHARMACEUTICALS INC | $53k 622 shares | -1% | - | |
| 51Moderate | REATA PHARMACEUTICALS INC | $316k 3,587 shares | -4% | - |
Transactions
Every row this insider has filed, 18 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | PLSE Pulse Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 15, 2026 |
| Jun 4, 2026 | SMMT Summit Therapeutics Inc. | POpen-market purchase Common Stock | +25,000 | $14.46 | $362k | 3,098,603 | Jun 4, 2026 |
| Jun 4, 2026 | SMMT Summit Therapeutics Inc. | POpen-market purchase Common Stock | +25,000 | $14.43 | $361k | 3,123,603 | Jun 4, 2026 |
| Oct 21, 2025 | SMMT Summit Therapeutics Inc. | AGrant or award Common Stock | +53,361 | $18.74 | $1000k | 3,073,603 | Oct 23, 2025 |
| Aug 15, 2025 | PLSE Pulse Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Aug 19, 2025 |
| Apr 29, 2025 | SMMT Summit Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +11,200,000 | - | - | 11,200,000 | May 1, 2025 |
| Sep 11, 2024 | SMMT Summit Therapeutics Inc. | AGrant or award Common Stock | +44,052 | $22.70 | $1000k | 3,020,242 | Sep 13, 2024 |
| Aug 23, 2024 | SMMT Summit Therapeutics Inc. | AGrant or award Performance Stock Option (right to buy)derivative | +2,800,000 | - | - | 2,800,000 | Aug 23, 2024 |
| Aug 9, 2024 | PLSE Pulse Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Aug 13, 2024 |
| Jun 6, 2024 | PLSE Pulse Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 24, 2024 |
| Apr 2, 2024 | SMMT Summit Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +1,100,000 | - | - | 1,100,000 | Apr 4, 2024 |
| Oct 13, 2023 | SMMT Summit Therapeutics Inc. | POpen-market purchase Common Stock | +2,976,190 | $1.68 | $5.0M | 2,976,190 | Oct 16, 2023 |
| Oct 13, 2023 | SMMT Summit Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +14,000,000 | - | - | 14,000,000 | Oct 16, 2023 |
| Mar 7, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -622 | $84.70 | $53k | 88,304 | Mar 8, 2023 |
| Mar 3, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -3,587 | $87.97 | $316k | 88,926 | Mar 6, 2023 |
| Feb 28, 2023 | RETA REATA PHARMACEUTICALS INC | AGrant or award Employee Stock Option (right-to-buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Mar 1, 2023 |
| Jan 3, 2023 | RETA REATA PHARMACEUTICALS INC | AGrant or award Class A common stock | +23,513 | $0.00 | $0 | 92,513 | Jan 4, 2023 |
| Jan 3, 2023 | RETA REATA PHARMACEUTICALS INC | AGrant or award Employee Stock Option (right-to-buy)derivative | +95,475 | $0.00 | $0 | 95,475 | Jan 4, 2023 |
Questions about Manmeet Singh Soni
Answered from the filings on this page, as of the latest one.
Is Manmeet Singh Soni buying or selling?
In the last 12 months Manmeet Singh Soni reported 1 open-market buy worth $722k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $722k of SMMT on Jun 4, 2026. Grants, option exercises and tax withholding are not counted.
How did Manmeet Singh Soni's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Manmeet Singh Soni has 1.
Where does Manmeet Singh Soni file Form 4?
Manmeet Singh Soni has filed Form 4 at RETA (REATA PHARMACEUTICALS INC) as COO, CFO and President; SMMT (Summit Therapeutics Inc.) as COO and CFO; PLSE (Pulse Biosciences, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.